Research & IP · Canada

AbCellera Biologics

AI-enabled antibody discovery platform that found bamlanivimab, the first authorised COVID-19 monoclonal antibody, in about 90 days under the DARPA pandemic-prevention programme.

Headquarters
Vancouver, Canada · North America
Value chain
Research & IP(Research & design); also Professional & data services
What that means
Invents and licenses: corporate and contract research, IP and technology licensing, with little production of its own.
Founded
2012
Ownership
Listed
Listing
Nasdaq:ABCL on Google Finance
Website
abcellera.com
Relevance
Moderate at its strongest, in Advanced Therapeutics, Vaccines & Medical Countermeasures

In 1 capability

Each capability the company is listed in, most relevant first: how experts in the field see its global relevance there, why it is listed and the source.

  1. Biotechnology & Health Technologies · Research · listed #35 of 50

    AI-enabled antibody discovery platform that found bamlanivimab, the first authorised COVID-19 monoclonal antibody, in about 90 days under the DARPA pandemic-prevention programme.

    Relevance: AI antibody discovery platform

    Source · en.wikipedia.org